Jeito
  • About
  • The team
  • Our portfolio
  • ESG & Impact
  • Newsroom
  • Contact
  • English
    • Français
    • English
Select Page

Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics

by Jeito Life | 29 Nov Tue | English

Deal validates Jeito’s unique investment model of selecting high-quality assets developed by world-leading teams in therapeutic areas with high unmet need Paris, France, November 29th 2022 – Jeito Capital (“Jeito”), the largest fully independent...

NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis

by Jeito Life | 11 Oct Tue | English

Aarhus, Denmark, 11 October 2022 – NMD Pharma A/S, a clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today reported positive top-line results from a Phase I/IIa clinical trial of NMD670,...

Jeito Capital co-leads €75 million Series B financing in SparingVision

by Jeito Life | 14 Sep Wed | English

Paris, France, September 14, 2022 – Jeito Capital (“Jeito”), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a Series B financing round in SparingVision, a privately held French biotech...

Jeito Capital co-leads $76 million Series A financing for CDR-Life its 10th investment since its launch

by Jeito Life | 13 Apr Wed | English

Paris, France, April 13, 2022 – Jeito Capital (“Jeito”), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a $76 million Series A financing round in CDR-Life, a privately-held biotech...

Jeito Capital co-leads EUR 80 million euro Series B financing in European oncology company, Precirix

by Jeito Life | 16 Mar Wed | English

Paris, France, March 2022, 16th – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led an investment of €80 million in Precirix, a clinical-stage biotechnology company developing...
« Older Entries

Recent Posts

  • Jeito Capital appoints Pascal Touchon as Operating Partner
  • Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women’s Health
  • Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders
  • Jeito Capital Strengthens Leadership for Next Chapter of Growth:Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
  • Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases

Recent Comments

    Mentions et autres liens
    Nous utilisons des cookies sur notre site Web pour vous offrir l'expérience la plus pertinente en mémorisant vos préférences et vos visites répétées.
    En cliquant sur "Accepter tout", vous consentez à l'utilisation de TOUS les cookies. Toutefois, vous pouvez visiter "Paramètres des cookies" pour fournir un consentement contrôlé.
    Cookie settingsAccept all
    Manage consent

    Privacy Overview

    Ce site web utilise des cookies pour améliorer votre expérience lorsque vous naviguez sur le site. Parmi ceux-ci, les cookies qui sont catégorisés comme nécessaires sont stockés sur votre navigateur car ils sont essentiels pour le fonctionnement des fonctionnalités de base du site web. Nous utilisons également des cookies tiers qui nous aident à analyser et à comprendre comment vous utilisez ce site web. Ces cookies ne seront stockés dans votre navigateur qu'avec votre consentement. Vous avez également la possibilité de refuser ces cookies. Mais la désactivation de certains de ces cookies peut affecter votre expérience de navigation.
    SAVE & ACCEPT